24 - "Hyper-accelerate clinical trials using an in silico approach"
Host:
Luca Emili
CEO of InSilicoTrials Technologies
Member of the Cloud Security Consultative Group in EMA
Responsible for the RCA Research Collaboration Agreement between InSilicoTrials and the FDA
Member of the committee for the adoption of the In Silico Medicine of the Italian Ministry of Health
Short Bio:
Luca Emili is an entrepreneur and investor, founder, and current CEO of InSilicoTrials Technologies, the first global platform that is making easy-to-use modeling and simulation to accelerate the pace of innovation in the healthcare and life science industry.
From 2001 to 2010 he was CEO of Emaze, a cybersecurity company that became one of the market leaders in Italy by automating security analysis for complex networks and devices.
Luca also worked in M&A and his many passions brought him to be a journalist, an entrepreneur in the internet services business, a startup investor and an IT lecturer at the MIB School of Management of Trieste. He has a degree in Economy and Business from the University of Trieste, Italy, where he still lives when he’s not traveling across the USA and Europe.
ABSTRACT:
We are living in a time of huge scientific innovation in the field of life sciences. The Covid-19 pandemic has shown how researchers and pharmaceutical companies can work fast and effectively, coming up with several vaccines in a few months instead of many years. This was possible also thanks to the use of in silico methods.
Drug development costs and timelines continue to increase. An in silico approach is key to hyper-accelerate clinical trials and cut up to 50% of the cost and time of drug and medical device development, while significantly reducing animal and human testing.
